Document is current
Any future updates will be listed below
-
Authors
Hesse, Swen https://orcid.org/0000-0002-2055-2764
Rullmann, Michael https://orcid.org/0000-0002-2683-9432
Günnewig, Tilman
Schweickert de Palma, Eva
Burmeister, Lara https://orcid.org/0009-0000-6463-959X
van Grinsven, Max https://orcid.org/0009-0001-5691-4720
Zientek, Franziska https://orcid.org/0000-0002-0580-8872
Luthardt, Julia
Hankir, Mohammed K. https://orcid.org/0000-0001-5218-9683
Meyer, Philipp M. https://orcid.org/0000-0002-4692-9320
Becker, Georg-Alexander https://orcid.org/0000-0002-7140-7436
Patt, Marianne https://orcid.org/0000-0001-6492-4104
Brust, Peter https://orcid.org/0000-0001-5555-7058
Pleger, Burkhard https://orcid.org/0000-0002-3956-9662
Stumvoll, Michael
Hilbert, Anja https://orcid.org/0000-0003-2775-1296
Blüher, Matthias https://orcid.org/0000-0003-0208-2065
Sabri, Osama https://orcid.org/0000-0002-6425-3504
-
Funding
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (01E01001)
- License Information
-
More Information
Article History
Received: 24 April 2025
Accepted: 12 August 2025
First Online: 17 September 2025
Competing interests
: S.H. received research grants from the German Federal Ministry of Education and Research, German Research Foundation, Innovation Fund, and Roland Ernst Foundation for Health Care; honoraria for lectures and travel grants from GE Healthcare, Bayer Pharma, and Hermes Medical Solutions. A.H. reports receiving research grants from the German Federal Ministry of Education and Research, German Research Foundation, Innovation Fund, and Roland Ernst Foundation for Health Care; royalties for books on the treatment of eating disorders and obesity with Hogrefe and Kohlhammer; honoraria for workshops and lectures on eating disorders and obesity and their treatment, including Lilly and Novo Nordisk; honoraria as editor of the International Journal of Eating Disorders; and honoraria as a consultant for Takeda. M.B. received honoraria for lectures or consultancy from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Lilly, MSS, Novo Nordisk, and Sanofi. The other authors declare no competing interests.
